Document is current
Any future updates will be listed below
-
Authors
Tuazon, J. A. https://orcid.org/0000-0001-9896-9714
Kilburg-Basnyat, B. https://orcid.org/0000-0002-6133-4800
Oldfield, L. M. https://orcid.org/0000-0003-0796-2192
Wiscovitch-Russo, R. https://orcid.org/0000-0002-1250-3129
Dunigan-Russell, K. https://orcid.org/0000-0002-3383-8446
Fedulov, A. V. https://orcid.org/0000-0002-8226-2236
Oestreich, K. J. https://orcid.org/0000-0002-3004-072X
Gowdy, K. M. https://orcid.org/0000-0002-7227-0697
- License Information
-
More Information
Article History
Accepted: 13 March 2022
First Online: 8 April 2022
Declarations
:
: Brita Kilburg-Basnyat reports being employed at Arcus Biosciences, Inc. as of 1/18/22. None of the work for this review paper was performed while employed by the biopharmaceutical company and the treatments Arcus is pursuing are oncology-related. Lauren Oldfield reports personal fees from Replay Holdings LLC, outside the submitted work. Jasmine Tuazon, Rosana Wiscovitch-Russo, Katelyn Dunigan-Russell, Alexey Fedulov, Kenneth Oestreich, and Kymberly Gowdy declare that they have no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
